Chlamydia trachomatis infection: Host immune responses and potential vaccines

Mucosal Immunology

Volumn 1, Issue 2, 2008, Pages 116-130

  Hafner, L ^a   Beagley, K ^a   Timms, P ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIAL DNA; BACTERIAL VACCINE; CHLAMYDIAL VACCINE; CLASS 1 ACCESSIBLE PROTEIN; CPG OLIGODEOXYNUCLEOTIDE; CYSTEINE RICH PROTEIN A; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA VACCINE; ENDOPEPTIDASE CLP; INACTIVATED VACCINE; LIVE VACCINE; MALTOSE BINDING PROTEIN; OUTER MEMBRANE PROTEIN; PROTEIN DERIVATIVE; RECOMBINANT PROTEIN; SUBUNIT VACCINE; T LYMPHOCYTE ANTIGEN; TC 0462; TC 0559;

ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CLINICAL FEATURE; DRUG DELIVERY SYSTEM; FEMALE GENITAL TRACT INFECTION; FEMALE INFERTILITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPATHOGENESIS; INNATE IMMUNITY; MUCOSA; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; SEROTYPE; VACCINATION;

EID: 48849101099     PISSN: 19330219     EISSN: None     Source Type: Journal    
DOI: 10.1038/mi.2007.19     Document Type: Review

References (197)

1. WHO. Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections: Overview and Estimates. World Health Organization, Geneva, Switzerland, 2001.
2. Blandford, J.M. & Gift, TL. Productivity losses attributable to untreated chlamydial infection and associated pelvic inflammatory disease in reproductive-aged women. Sex. Transm. Dis. 33, S117-S121 (2006).
3. CDC. Sexually Transmitted Disease Surveillance 2005 Supplement, Chlamydia Prevalence Monitoring Project Annual Report 2005. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA, December 2006.
4. Stamm, W.E. Chlamydia trachomatis infections: Progress and problems. J. Infect. Dis. 179 (Suppl 2), S380-S383 (1999).
5. Pimenta, J.M. et al. Opportunistic screening for genital chlamydia infection II: Prevalence among healthcare attendees, outcome and evaluation of positive cases. Sex. Transm. Infect. 79, 22-27 (2003).
6. Weinstock, H., Berman, S. & Cates, W. Jr. Sexually transmitted diseases among American youth: Incidence and prevalence estimates, 2000. Perspect. Sex. Reprod. Health 36, 6-10 (2004).
7. Abdel Rahman, Y.M. & Belland, R.J. The chlamydial developmental cycle. FEMS Microbiol. Rev. 29, 949-959 (2005).
8. Stephens, R.S., Poteralski, J.M. & Olinger, L. Interaction of Chlamydia trachomatis with mammalian cell is independent of host cell surface heparan sulphate glycosaminoglycans. Infect. Immun. 74 1795-1799 (2006).
9. Hackstadt, T. Cell biology. In Chlamydia: Intracellular Biology, Pathogenesis and Immunity (Stephens, R.S., ed) 101-139 (ASM Press, Washington, DC, 1999).
10. Van Ooij, C., Apodaca, G. & Engel, J.N. Characterization of the Chlamydia trachomatis vacuole and its interaction with the host endocytic pathway in HeLa cells. Infect. Immun. 65, 758-766 (1997).
11. Wyrick, PB. Intracellular survival by Chlamydia. Cell. Microbiol. 2, 275-282 (2000).
12. Davis, C. & Raulston, J.E. Protein disulfide isomerase, a component of the estrogen receptor complex, is associated with Chlamydia trachomatis serovar E attached to human endometrial epithelial cells. Infect Immun. 70, 3413-3418 (2002).
13. Kutlin, A., Roblin, P.M. & Hammerschlag, M.R. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. Antimicrob. Agents Chemother. 43 2268-2272 (1999).
14. Hanada, H., Ikeda-Dantsuji, Y. & Naito, M. Infection of human fibroblast-like synovial cells with Chlamydia trachomatis results in persistent infection and interleukin-6 production. Microb. Pathog. 34, 57-63 (2003).
15. Coles, A.M. et al. Low-nutrient induction of abnormal chlamydial development: A novel component of chlamydial pathogenesis? FEMS Microbiol. Lett. 106, 193-200 (1993).
16. Hogan, R.J. et al. Chlamydial persistence: Beyond the biphasic paradigm. Infect. Immun. 72, 1843-1855 (2004).
17. Patton, D. L. et al. Detection of Chlamydia trachomatis in fallopian tube tissue in women with postinfectious tubal infertility. Am. J. Obstet. Gynecol. 171, 95-101 (1994).
18. Holland, S.M. et al. Demonstration of chlamydial RNA and DNA during a culture-negative state. Infect. Immun. 60, 2040-2047 (1992).
19. Nanagara, R. et al. Alteration of Chlamydia trachomatis biologic behaviour in synovial membranes: Suppression of surface antigen production in reactive arthritis and Reiter's syndrome. Athritis Rheum. 38, 1410-1417 (1995).
20. Dean, D., Suchland, R.J. & Stamm, W.E. Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping. J. Infect. Dis. 182, 909-916 (2000).
21. Bragina, E.Y., Gomberg, M.A. & Dmitriev, G.A. Electron microscopic evidence of persistent chlamydial infection following treatment. J. Eur Acad. Dermatol. Venereol. 15, 405-409 (2001).
22. Bazala, E. & Renda, J. Latent chlamydial infections: The probable cause of a wide spectrum of human diseases. Med. Hypotheses 65, 578-584 (2005).
23. Mpiga, P. & Ravaoarioro, M. Chlamydia trachomatis persistence: An update. Microbiol. Res. 161, 9-19 (2006).
24. Molano, M. et al. Combination of PCR targeting the VD2 of omp1 and reverse line blot analysis for typing of urogenital Chlamydia trachomatis serovars in cervical scrape specimens. J. Clin. Microbiol. 42, 2935-2939 (2004).
25. Xiong, L. et al. Use of PCR and reverse line blot hybridisation assay for simultaneous detection and serovar identification of Chlamydia trachomatis. J. Clin. Microbiol. 44, 1413-1418 (2006).
26. Yang, C.L., Maclean, I. & Brunham, R.C. DNA sequence polymorphism of the Chlamydia trachomatis omp1 gene. J. Infect. Dis. 168, 1225-1230 (1993).
27. Dean, D., Oudens, E., Bolan, G., Padian, N. & Schachter, J. Major outer membrane protein variants of Chlamydia trachomatis are associated with severe upper genital tract infections and histopathology in San Francisco. J. Infect. Dis. 172, 1013-1022 (1995).
28. Rodriguez, P. et al. Evaluation of molecular typing for epidemiological study of Chlamydia trachomatis genital infections. J. Clin. Microbiol. 31, 2238-2240 (1993).
29. Kuo, C.-C. et al. Immunotypes of Chlamydia trachomatis isolates in Seattle, Washington. Infect. Immun. 41, 865-868 (1983).
30. Spaargaren, J. et al. Analysis of Chlamydia trachomatis serovar distribution changes in the Netherlands (11986-2002). Sex. Transm. Infect. 80, 151-156 (2004).
31. Chungue, E. et al. Immunotypes of Chlamydia trachomatis isolated from genital tract specimens in Tahiti. Eur. J. Clin. Mcrobiol. Infect. Dis. 13, 436-438 (1994).
32. Millman, K. et al. Population-based genetic and evolutionary analysis of Chlamydia trachomatis urogenital strain variation in the United States. J. Bacteriol. 186, 2457-2465 (2004).
33. Barnes, R.C., Rompala, A.M. & Srtamm, W.E. Comparison of Chlamydia trachomatis serovars causing rectal and cervical infections. J. Infect. Dis. 156, 953-958 (1987).
34. Gomes, J. P. et al. Correlating Chlamydia trachomatis infectious load with urogenital ecologicad success and disease pathogenesis. Microbes Infect. 8, 16-26 (2006).
35. Lan, J. et al. Prevalence and serovar distribution of asymptomatic cervical Chlamydia trachomatis infections as determined by highly sensitive PCR. J. Clin. Microbiol. 33, 3194-3197 (1995).
36. Workowski, K.A. et al. Association of genital infection with specific Chlamydia trachomatis serovars and race. J. Infect. Dis. 166, 1445-1449 (1992).
37. Geisler, W.M., Suchland, R.J. & Stamm, W.E. Association of Chlamydia trachomatis serovar la infection with black race in a sexually transmitted disease clinic patient population in Birmingham, Alabama. Sex. Transm. Dis. 33, 621-624 (2006).
38. Gomes, J. P. et al. Correlating Chlamydia trachomatis infectious load with urogenital ecological success and disease pathogenesis. Microbes Infect. 8, 16-26 (2006).
39. Geisler, W.M. Approaches to the management of uncomplicated genital Chlamydia trachomatis infections. Expert Rev. Anti Infect. Ther. 2, 771-785 (2004).
40. Stamm, W.E. Chlamydia trachomatis - the persistent pathogen. Sex. Transm. Dis. 28, 684-689 (2001).
41. Fortenberry; J.D. et al. Subsequent sexually transmitted infections among adolescent women with genital infection due to Chlamydia trachomatis, Nsisseria gonorrhoeae, or Trichomonas vaginalis. Sex Transm. Dis. 26, 26-32 (1999).
42. Wyrick, P.B. & Knight, S.T. Pre-exposure of infected human endometrial epithelial cells to penicillin in vitro renders Chlamydia trachomatis refractory to azithromycin. J. Andmicrob. Chemother. 54, 79-85 (2004).
43. Horner, P. The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection. Sex. Transm. Infect. 82, 340-343 (2006).
44. Weisenfeld, H.C. et al. Association between devated neutrophil defensin level and endometritis. J. Infect. Dis. 186, 792-797 (2002).
45. Koskela, P. et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int. J. Cancer 85, 35-39 (2000).
46. Samoff, E. et al. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am. J. Epidemiol. 162, 668-675 (2005).
47. Plummer, F.A. et al. Co-factors in male-female sexual transmission of human immunodeficiency virus type 1. J. Infect Dis. 163, 233-239 (1991).
48. Brunham, R.C. & Rey-Ladino, J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat. Rev. Immunol. 5, 149-161 (2005).
49. Ramsey, K.H. et al. Expression of matrix metalloproteinases subsequent to urogenital Chlamydia muridarum infection of mice. Infect. Immun. 73, 6962-6973 (2005).
50. Shah, A.A. et al. Histopathologic changes related to fibrotic oviduct occlusion after genital tract infection of mice with Chlamydia muridarum. Sex. Transm. Dis. 32, 49-56 (2005).
51. Imtiaz, M.T. et al. Inhibition of matrix metalloproteinases protects mice from ascending infection and chronic disease manifestations resulting from urogenital Chlamydia muridarum infection. Infect. Immun. 74, 5513-5521 (2006).
52. Bachmaier, K. & Penninger, J.M. Chlamydia and antigenic mimicry. Curr. Top. Microbiol. Immunol. 296, 153-163 (2005).
53. Yi, Y., Yang, X. & Brunham, R.C. Autoimmunity to heat shock protein 60 and antigen-specific production of interleukin-10. Infect. Immun. 65, 1669-1674 (1997).
54. Allen, J.E. & Stephens, R.S. Identification by sequence analysis of 2-site posttranslational processing of the cysteine-rich outer-membrane protein-2 of Chlamydia trachomatis serovar L2. J. Bacteriol. 171, 285-291 (1989).
55. Kinnunen, A. et al. Chlamydia trachomatis reactive T lymphocytes from upper genital tract tissue specimens. Hum. Reprod. 15, 1484-1489 (2000).
56. Kinnunen, A. et al. Chlamyclial heat shock protein 60-specific T cells in inflamed salpingeal tissue. Fertil. Steril. 77, 162-166 (2002).
57. Kinnunen, A. et al. Chlamydia trachomatis heat shock protein-60 induced interferon-gamma and interleukin-10 production in infertile women. Clin. Exp. Immunol. 131, 299-303 (2003).
58. Tiitinen, A. et al. Chlamydia trachomatis and chlamydial heat-shock protein 60-specific antibody and cell-mediated responses predict tubal factor infertility. Hum. Reprod. 21, 1533-1538 (2006).
59. Larue, R.W., Dill, B.D., Gilés, D.K., Whittimore, J.D. & Raulston, J.E. Chlamydal Hsp60-2 is iron-responsive in Chlamydia trachomatis serovar E-infected human endometrial epithelial cells in vitro, Infect. Immun. 75, 2374-2380 (2007).
60. LaVerda, D. et al. Seroreactivity to Chlamydia trachomatis Hsp10 correlates with severity of human genital tract disease. Infect. Immun. 68, 303-309 (2000).
61. Betsou, F. et al. Cross-reactivity between Chlamydia trachomatis heat shock protein 10 and early pregnancy factor. Clin. Diagn. Lab. Immunol. 10, 446-450 (2003).
62. den Hartog, J. E. et al. Do host genetic traits in the bacterial sensing system play a role in the development of Chlamydia trachomatis-associated tubal pathology in subfertile women? BMC Infect. Dis. 6, 122 (2006).
63. Wira, C.R. et al. Innate and adaptive immunity in female genital tract: Cellular responses and interactions. Immunol. Rev. 206 306-335 (2005).
64. Yeaman, G. R. et al. CD8+ T cells in human uterine endometrial lymphoid aggregates: Evidence for accumulation of cells by trafficking. - Immunology 102, 434-440 (2001).
65. Mestecky J., Moldoveanu, Z. & Russell, M. Immunologic uniqueness of the genital tract: Challenge for vaccine development. Am. J. Reprod. Immunol. 53, 208-214 (2005).
66. Medzhitov, R. & Janeway, C.A. Jr. Toll receptor family and microbial recognition. Trends Microbiol. 8, 452-456 (2000).
67. Wira, C.R., Grant-Tschudy, K.S. & Crane-Godreau, M.A. Epithelial cells in the female reproductive tract: A central role as sentinels of immune protection. Am. J. Reprod. Immunol. 53, 65-76 (2005).
68. Severin, J.A. & Ossewaarde, J.M. Innate immunity in defense against Chlamydia trachomatis infections. Drugs Today (Barc) 42 (Suppl. A), 75-81 (2006).
69. Dessus-Babus, S. et al. Differences in innate immune responses (in vitro) to HeLa cells infected with nondisseminating serovar E and disseminating serovar L2 of Chlamydia trachomatis. Infect. Immun. 70, 3234-3248 (2002).
70. Entrican, G. et al. Induction of inflammatory host immune responses by organisms belonging to the genera Chlamydia/ Chlamydophila. Vet. Immunol. Immunopathol. 100, 179-186 (2004).
71. Rasmussen, S.J. et al. Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J. Clin. Invest. 99, 77-87 (1997).
72. Vabulas, R.M. et al. Endocytosed HSP60s use Toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells. J. Biol. Chem. 276, 31332-31339 (2001).
73. Welter-Stahl, L. et al. Stimulation of the cytosolic receptor for peptidoglycan, Nod1, by infection with Chlamydia trachomatis or Chlamydia muridarum. Cell. Microbiol. 8, 1047-1057 (2006).
74. Schnare, M. et al. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2, 947-950 (2001).
75. Derbigny, W.A., Kerr, M.S. & Johnson, R.M. Pattern recognition molecules activated by Chlamydia muridarum infection of cloned murine oviduct epithelia) cell lines. J. Immunol. 175, 6065-6075 (2005).
76. Darville, T. et al. Toll-like receptor-2, but not Toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. J. Immunol. 171, 6187-6197 (2003).
77. Nagarajan, U.M. et al. Chlamydia trachomatis induces expression of IFN-gamma-inducible protein 10 and IFN-beta independent of TLR2 and TLR4, but largely dependent on MyD881. J. Immunol. 175, 450-460 (2005).
78. Imtiaz, M.T. et al. Outcome of urogenital infection with Chlamydia muridarum in CD14 gene knockout mice. BMC Infect. Dis. 6, 144-149 (2006).
79. O'Connell, C.M. et al. Localization of TLR2 and MyD88 to Chlamydia trachomatis inclusions. Evidence for signaling by intracellular TLR2 during infection with an obligate intracellular pathogen. J. Biol. Chem. 281, 1652-1659 (2006).
80. Derbigny, W.A. et al. Chlamydia muridarum infection elicits a beta interferon response in murine oviduct epithelial cells dependent on interferon regulatory factor 3 and TRIF. Infect. Immun. 75, 1280-1290 (2007).
81. Hook, C. E. et al. Effects of Chlamydia trachomatis infection on the expression of natural killer (NK) cell ligands and susceptibility to NK cell lysis. Clin. Exp. Immunol. 138, 54-60 (2004).
82. Hook, C.E., Matyszak, M.K. & Gaston, J.S. Infection of epithelial and dendritic cells by Chlamydia trachomatis results in IL-18 and IL-12 production, leading to interferon-gamma production by human natural killer cells. FEMS Immunol. Med. Microbiol. 45, 113-120 (2005).
83. Shemer-Avni, Y., Wallach, D. & Sarov, I. Reversion of the antichlamydial effect of tumor necrosis factor by trypitophan and antibodies to beta interferon. Infect. Immun. 57, 3484-3490 (1989).
84. Decker, T., Muller, M. & Stockinger, S. The yin and yang of type I interferon activity in bacterial infection. Nat. Rev. Immunol. 5, 675-687 (2005).
85. Reis e Sousa, C. Activation of dendritic cells: Translating innate into adaptive immunity. Curr. Opin. Immunol. 16, 21-25 (2004).
86. Hanenberg, B., Kendall, D., Amerongen, H.M., Apter, F.M., Kraehenbuhl, J.P. & Neutra, M.R. Induction of specific immunoglobulin A in the small intestine, colon - rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect. Immun. 62, 15-23 (1994).
87. Kozlowski, P.A. et al. Mucosal vaccination strategies for women. J. Infect. Dis. 179 (Suppl 3), S493-S498 (1999).
88. Gould, D.S., Ploegh, H.L. & Schust, D.J. Murine female reproductive tract intraepithelial lymphocytes display selection characteristics distinct from both peripheral and other mucosal T cells. J. Rporod. Immunol. 52, 85-99 (2001).
89. Kelly, K.A. et al. Differential regulation of CD4 lymphocyte recruitment between the upper and lower regions of the genital tract during Chlamydia trachomatis infection. Infect. Immun. 68 1519-1528 (2000).
90. Su, H. et al. Chlamydia trachomatis genital tract infection of antibody-deficient gene knockout mice. Infect. Immun. 65, 1993-1999 (1997).
91. Hawkins, R.A., Rank, R.G. & Kelly, K.A. A Chlamydia trachomatis specific Th2 clone does not provide protection against a genital infection and displays reduced trafficking to the infected genital mucosa. Infect. Immun. 70, 5132-5139 (2002).
92. Williams, D.M. et al. Humoral and cellular immunity in secondary infection due to murine Chlamydia trachomatis. Infect. Immun. 65, 2876-2882 (1997).
93. Yang, X. & Brunham, R.C. Gene knockout B cell-deficient mice demonstrate that B cells play an important role in the initiation of T cell responses to Chlamydia trachomatis (mouse pneumonitis) lung infection. J. Immunol. 161, 1439-1446 (1998).
94. Johasson, M., Ward, M. & Lycke, N. B-cell deficient mice develop complete immune protection against genital tract infection with Chlamycia trachomatis. Immunology 92, 422-428 (1997).
95. Moore, T et al. Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J. Infect. Dis. 188 617-624 (2003).
96. Morrison, S.G. & Morrison, R.P. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J. Immunol. 175, 7536-7542 (2005).
97. Morrison, S.G. & Morrison, R. P. Humoral immunity to Chlamydia muridarum genital tract infection. In Proceedings of the 11th International Symposium on Human Chlamydial Infection, (Niagara-on-the-Lake, ON, Canada, 2006).
98. Hickey, D.K. et al. Intranasal immunization with C. muridarum major outer membrane protein (MOMP) and cholera toxin elicits local production of neutralising IgA in the prostate. Vaccine 22, 4306-4315 (2004).
99. Igietseme, J.U. et al. Route of infection that induces a high intensity of gamma interferon-secreting T Galls in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice. Infect. Immun. 66, 4030-4035 (1998).
100. Pal, S., Peterson, E.M. & De la Maza, L.M. Intranasal immunization induces long-term protection in mice against a Chlamydia trachomatis genital challenge. Infect. Immun. 64, 5341-5348 (1996).
101. Pal, S. et al. Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect. Immun. 62, 3354-3362 (1994).
102. Pal, S. et al. Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge. Infect. Immun. 65, 3361-3369 (1997).
103. Zhang, D. et al. Immunity to Chlamydia trachomatis mouse pneumonitis induced by vaccination with live organisms correlates with early granulocyte - macrophage colony-stimulating factor and interleukin-12 production and with dendritic cell-like maturation. Infect. Immun. 67, 1606-1613 (1999).
104. Brunham, R.C. & Zhang, D. Transgene as vaccine for chlamydia. Am. Heart J. 138 (5 Part 2), S519-S522 (1999).
105. Moore, T et al. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology 105, 213-221 (2002).
106. Igietseme, J.U. et al. Developing effective delivery systems for Chlamydia vaccines. Curr. Opin. Mol. Thar. 6, 182-194 (2004).
107. Kelly, K.A. T-lymphocyte trafficking to the female reproductive tract mucosae. In Chlamydia: Genomics and Pathogenesis (Bavoil, P. M. & Wyrick, P.B., eds) 413-435 (Horizon Bioscience, Norfolk. UK, 2006).
108. Morrison, R.P., Feilzer, K. & Tumas, D.B. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect. Immun. 63, 4661-4668 (1995).
109. Su, H. & Caldwell, H.D. CD4+ T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract. Infect. Immun. 63, 3302-3308 (1995).
110. Rank, R.G. & Sanders, M.M. Pathogenesis of endometritis and salpingtis in a guinea pig model of [chlamydial genital infection. Am. J. Pathol. 140, 927-936 (1992).
111. Zhong, G., Fan, T. & Liu, L. Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. J. Exp. Med. 189 1931-1938 (1999).
112. Igietseme, J.U. The molecular mechanism of T-cell control of Chlamydia in mice: Role of nitric oxide. Immunology 87, 11-8 (1996).
113. Loomis, W.P. & Stambach, M.N. T cell responses to Chlamydia trachomatis. Curr. Opin. Microbiol. 5, 87-91 (2002).
114. Pudney, J., Quayle, A.J. & Anderson, D.J. Immunological microenvironments in the human vagina and cervix: Mediators of cellular immunity are concentrated in the cervical transformation zone. Biol. Reprod. 73, 1253-1263 (2005).
115. Parr, M.B. & Parr, E.L. Antigen recognition in the female reproductive tract: I. Uptake of intraluminal protein tracers in the mouse vagina. J. Reprod. Immunol. 17, 101-114 (1990).
116. Miller, C.J., McChesney, M. & Moore, P.F. Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of rhesus macaques. Lab. Invest. 67, 628-634 (1992).
117. Shaw, J.H. et al. Expression of genes encoding Th1 cell-activating cytokines and lymphoid homing chemokines by chlamydia-pulsed denddtic cells correlates with protective immunizing efficacy. Infect. Immun. 69, 4667-4672 (2001).
118. Matyszak, M.K. & Gaston, J.S. Chlamydia trachomatis-specific human CD8+ T cells show two patterns of antigen recognition. Infect. Immun. 72, 4357-4367 (2004).
119. Rey-Ladino, J. et al. A live and inactivated Chlamydia trachomatis mouse pneumonitis strain induces the maturation of dendritic cells that are phenotypically and immunologically distinct. Infect Immun. 73, 1568-1577 (2005).
120. Zaharik, M. L. et al. Genetic profiling of dendritic cells exposed to live- or ultraviolet-irradiated Chlamydia muridarum reveals marked differences in CXC chemokine profiles. Immunology 120 160-172 (2006).
121. Reddy, B.S. et al. Cytokine expression pattern in the genital tract of Chlamydia trachomatis positive infertile women - implication for T-cell responses. Clin. Exp. Immunol. 137, 552-558 (2004).
122. Wang, C. et al. Interleukin (IL)-2 and IL-12 responses to Chlamydia trachomatis infection in adolescents. Clin. Exp. Immunol. 142, 548-554 (2005).
123. Roan, N.R. et al. Monitoring the T cell response to genital tract infection. Proc. Natl. Acad. Sci, USA 103, 12069-12074 (2006).
124. Roan, N.R. & Stambach, M.N. Antigen-specific CD8+ T cells respond to Chlamydia trachomatis in the genital mucosa. J. Immunol. 177 7974-7979 (2006).
125. Rank, R.G. The role of CD4 T cell in the host response to Chlamydia. In Chlamydia: Genomics and Pathogenesis (Bavoil, P.M. & Wyrick, P.B., eds) 365-381 (Horizon Bioscience, Norfolk, UK, 2006).
126. Lyons, J. An integrated approach to the study of Chlamydia trachomatis infection of the female genital tract. Drugs Today 42 (Suppl A), 83-97 (2006).
127. Vanrompay, D., Lyons, J.M. & Morre, S.A. Animal models for the study of Chlamydia trachomatis infections in the female genital infection. Dugs Today 42 (Suppl A), 55-63 (2006).
128. Morrison, R. P. & Caldwell, H.D. Immunity to murine chlamydial genital infection. Infect. Immun. 70, 2741-2751 (2002).
129. Rank, R.G. Models of immunity. In Chlamydia: Intracellular Biology, Pathogenesis and Immunity (Stephens, R.S., ed) 239-295 (American Society for Microbiology, Washington, DC, 1999).
130. Tuffrey, M. et al. Genetic susceptibility to chlamydial salpingitis and subsequent infertility in mice. J. Reprod. Fertil. 95, 31-38 (1992).
131. Darville, T. et al. Mouse strain-dependent variation in the course and outcome of chlamydial genital tract infection is associated with differences in host response. Infect. Immun. 65, 3065-3073 (1997).
132. Ramsey, K.H., DeWolfe, J.L. & Salyer, R.D. Disease outcome subsequent to primary and secondary urogenital infection with murine or human biovars of Chlamydia trachomatis. Infect. Immun. 68, 7186-7189 (2000).
133. Barron, A.L., White, H.J., Rank, R.G., Soloff, B.L. & Moses, E.B. A new animal model for the study of Chlamiydia trachomatis genital infections: Infection of mice with the agent of mouse pneumonitis. J. Infect Dis. 143, 63-66 (1981).
134. Morrison, S.G. & Morrison, R.P. In situ analysis of the evolution of the primary immune response in murine Chlamydia trachomatis genital tract infection. Infect. Immun. 68, 2870-2879 (2000).
135. Morre, S.A. et al. Prevalence and serovar distribution of asymptomatic cervical Chlamydia trachomatis infections as determined by highly sensitive PCR. J. Clin. Microbiol. 38, 2292-2296 (2000).
136. Roshick, C. et al. Comparison of gamma interferon-mediated antichlamydial defense mechanisms in human and mouse cells. Infect. Immun. 74, 225-238 (2006).
137. Nelson, D.E. et al. Chlamydial IFN-gamma immune evasion is linked to host infection tropism. Proc. Natl. Acad. Sci. USA 102, 10658-10663 (2005).
138. Yasui, H. et al. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: Its possible occurrence in cancer patients. Proc. Natl. Acad. Sci. USA 83, 6622-6626 (1986).
139. Thomas, S.M. et al. IFN-gamma-mediated antimicrobial response. Indoleamine 2,3-dioxygenase-deficient mutant host cells no longer inhibit intracellular Chlamydia spp. or Toxoplasma growth. J. Immunol. 150, 5529-5534 (1993).
140. McClarty, G., Caldwell, H.D. & Nelson, D.E. Chlamydial interferon gamma immune evasion influences infection tropism. Curr. Opin. Microbiol. 10, 47-51 (2007).
141. Mount, D.T., Bigazzi, P. & Barron, A.L. Experimental genital infection of male guinea pigs with the agent of guinea pig inclusion conjunctivitis and transmission to females. Infect. Immun. 8 925-930 (1973).
142. Rank, R.G. et al. Characterization of chlamydial genital infection resulting from sexual transmission from male to female guinea pigs and determination of infectious dose. Infect. Immun. 71, 6148-6154 (2003).
143. Bannantine, J.P. & Rockey, D.D. Use of primate model system to identify Chlamydia trachomatis protein antigens recognized uniquely in the context of infection. Microbiology 145 (Part 8), 2077-2085 (1999).
144. Van Voorhis, W.C. et al. Repeated Chlemyola trachomatis infection of Macaca nemestrina fallopian tubes produces a Th1-like cytokine response associated with fibrosis and scarring. Infect. Immun. 65, 2175-2182 (1997).
145. Patton, D.L. et al. Effects of doxycycline and antiinflammatory agents on experimentally induced chlamydial upper genital tract infection in female macaques. J. Infect. Dis. 175, 648-654 (1997).
146. Lichtenwalner, A.B. et al. Evidence of genetic susceptibility to Chlamydia trachomatis-induced pelvic inflammatory disease in the pig-tailed macaque. Infect. Immun. 65, 2250-2253 (1997).
147. Peeling, R.W. et al. Antibody response to the chlamydial heat-shock protein 60 in an experimental model of chronic pelvic inflammatory disease in monkeys (Macaca nemestrina). J. Infect. Dis. 180, 774-779 (1999).
148. Patton, D. L., Sweeney, Y.T. & Stamm, W.E. Significant reduction in inflammatory response in the macaque model of chlamydial pelvic inflammatory disease with azithromycin treatment. J. Infect. Dis. 192, 129-135 (2005).
149. Bannantine, J.P. & Rockey D.D. Use of primate model system to identify Chlamydia trachomatis protein antigens recognized uniquely in the context of infection. Microbiology 145 (Part 8), 2077-2085 (1999).
150. Tuggle, C. K. et al. EST-based gene discovery in pig: Virtual expression patterns and comparative mapping to human. Mamm. Genome 14, 565-579 (2003).
151. Vanrompay, D. et al. Specific-pathogen-free pigs as an animal model for studying Chlamydia trachomatis genital infection. Infect. Immun. 73, 8317-8321 (2005).
152. Zaharik, M.L. et al. Genetic profiling of dendritic cells exposed to live- or ultraviolet-irradiated Chlaroydia muridarum reveals marked differences in CXC chemokine profiles. Immunology 120 160-172 (2007).
153. He, Q. et al. Live-attenuated influenza viruses as delivery vectors for Chlamyoia vaccines. Immunology 23, 1-10 (2007).
154. Collier, L.H. & Blyth, W.A. Immunogenicity of experimental trachoma vaccines in baboons. III. Experiments with inactivated vaccines. J. Hyg. (Gambridge) 65, 97-107 (1967).
155. Wang, S.P., Grayston, J.T. & Alexander, E.R. Trachoma vaccine studies in monkeys. Am. J. Ophthalmol. 63, 1615-1630 (1967).
156. Woolridge, R.L. et al. Long-term follow-up of the initial (1959-1960) trachoma vaccine field trail on Taiwan. Am. J. Ophthalmol. 63, 1650-1653 (1967).
157. Batteiger, B.E. et al. Partial protection against genital reinfection by immunization of guinea-pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjunctivitis. J. Gen. Microbiol. 139 (Part 12), 2965-2972 (1993).
158. Brunham, R.C. & Peeling, R.W. Chlamydia trachomatis antigens: Role in immunity and pathogenesis. Infect. Agents Dis. 3, 218-233 (1994).
159. Dong-Ji, Z. et al. Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses. Infect. Immun. 68 3074-3078 (2000).
160. Su, H., Parnell, M. & Caldwell, H.D. Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection. Vaccine 13, 1023-1032 (1995).
161. Zhang, D. et al. DNA vaccination with the major outer-membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection. J. Infect. Dis. 176, 1035-1040 (1997).
162. Pal, S. et al. Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine 17, 459-465 (1999).
163. Conlan, J.W. et al. Isolation of recombinant fragments of the major outer-membrane protein of Chlamydia trachomatis: Their potential as subunit vaccines. J. Gen. Microbiol. 136, 2013-2020 (1990).
164. Hayes, L.J. et al. Chlamydia trachomatis major outer membrane protein epitopes expressed as fusions with LamB in an attenuated aro A strain of Salmonella typhimurium; their application as potential immunogens. J. Gen. Microbiol. 137, 1557-1564 (1991).
165. Tan, T.W. et al. Protection of sheep against Chlamydia psittaci infection with a subcellular vaccine containing the major outer membrane protein Infect. Immun. 58, 3101-3108 (1990).
166. Taylor, H. R. et al. Oral immunizatbn with chlamydal major outer membrane protein (MOMP). Invest. Ophthalmol. Vis. Sci. 29, 1847-1853 (1988).
167. Tuffrey, M., Alexander, F., Conlan, W., Woods, C. & Ward, M. Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar Fisolate of Chlamycia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane protein. J. Gen. Microbiol. 138 (Part 8), 1707-1715 (1992).
168. Zhong, G., Smith, G.P., Berry, J. & Brunham, R.C. Conformational mimicry of a chlamydial neutralization epitope on filamentous phage. J. Biol. Chem. 269, 24183-24188 (1994).
169. McNeilly, C.L. et al. Expression library immunization confers partial protection against Chlamydia muridarum genital infection. Vaccine 25, 2643-2655 (2007).
170. Stephens, R.S. Chlamydial genomics and vaccine antigen discovery. J. Infect. Dis. 181, S521-S523 (2000).
171. Kalman, S. et al. Comparative genomes of Chlamydia pneumoniae and C. trachomatis. Nat. Genet. 21, 385-389 (1999).
172. Stephens, R.S. et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis [see comments]. Science 282, 754-759 (1998).
173. Murdin, A.D. et al. Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection. J. Infect. Dis. 181 (Suppl 3), S544-S551 (2000).
174. Rosenthal, K.S. & Zimmerman, D. H. Vaccines: All things considered. Clin. Vaccine Immunol. 13, 821-829 (2006).
175. Pal, S. et al. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect. Immun. 69 6240-6247 (2001).
176. Berry, L.J. et al. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect. Immun. 72, 1019-1028 (2004).
177. Eko, F.O. et al. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vacanating against Chlamydia trachomatis. Vaccine 21, 1694-1703 (2003).
178. Pal, S., Peterson, E.M. & de la Maza, L.M. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect. Immun. 73, 8153-8160 (2005).
179. Pal, S. et al. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. Vaccine 24, 766-775 (2006).
180. Pal, S., Peterson, E.M. & de la Maza, L.M. Vaccination of newborn mice induces a strong protective immune response against respiratory and genital challenges with Chlamydia trachomatis. Vaccine 23, 5351-5358 (2005).
181. Singh, S.R. et al. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection. Vaccine 24, 1213-1224 (2006).
182. Pal, S., Peterson, E.M. & de la Maza, L.M. Induction of protective immunity against a Chlamydia trachomatis genital infection in three genetically distinct strains of mice. Immunology 110, 368-375 (2003).
183. Lyons, J.M. et al. Comparison of multiple genital tract infections with Chlamyodia trachomatis in different strains of female mice. J. Microbiol. Immunol. Infect. 38, 383-393 (2005).
184. Eko, F.O. et al. A novel recombinant multisubunit vaccine against Chlamydia. J. Immunol. 173, 3375-3382 (2004).
185. Su, H. et al. Subclinical chlamydial infection of the female mouse genital tract generates a potent protective immune response: implications for development of live attenuated chlamydial vaccine strains. Infect. Immun. 68, 192-196 (2000).
186. Macmillan, L. et al. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. FEMS Immunol. Med. Microbiol. 49, 46-55 (2007).
187. He, Q. et al. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. Immunology 122, 28-37 (2007).
188. Pal, S. et al. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Vaccine 21, 1455-1465 (2003).
189. Lyons, J.M. et al. Acquired homotypic and heterotypic immunity against oculogenital Chlamydia trachomatis serovars following female genital tract infection in mice. BMC Infect. Dis. 6, 105-113 (2005)
190. Murthy, A.K. et al. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele. Infect. Immun. 74, 6722-6729 (2006).
191. Murthy, A.K. et al. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect. Immun. 75, 666-676 (2007).
192. Cong, Y. et al. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Vaccine 25, 3773-3780 (2007).
193. Stambach, M.N. et al. An inclusion membrane protein from Chlamydia trachomatis enters the MHC class I pathway and stimulates a CD8+ T cell response. J. Immunol. 171, 4742-4749 (2003).
194. Roan, N.R. et al. Monitoring the T cell response to genital tract infection. Proc. Natl. Acad. Sci. USA 103, 12069-12074 (2006).
195. Fling, S.P. et al. CD8+ T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen Chlamydia trachomatis. Proc. Natl. Acad. Sci. USA 98, 1160-1165 (2001).
196. Whittum-Hudson, J.A. et al. The anti-idiotypic antibody to chlamydial glycolipid exoantigen (GLXA) protects mice against genital infection with a human biovar of Chlamydia trachomatis. Vaccine 19, 4061-4071 (2001).
197. Donati, M. et al. DNA immunization with pgp3 gene of Chlamydia trachomatis inhibits the spread of chlamydial infection from the lower to the upper genital tract in C3H/HeN mice. Vaccine 21, 1089-1093 (2003).